Inovio Pharmaceuticals stock trades lower as FDA date nears

Inovio Pharmaceuticals stock (ISIN US45773H4092) stood at USD 1.25 after hours on Nasdaq on September 23, 2026, down USD 0.04, or 3.10 percent, from the prior close. The company now approaches a defined regulatory checkpoint for its lead candidate INO-3107.

FDA decision sets the next test

As Yahoo Finance reported on September 11, 2026, the FDA is reviewing Inovio's biologics license application for INO-3107 under the accelerated approval program. The target action date is October 30, 2026, while late-cycle review and scheduled inspections have been completed.

The clinical evidence supplies the measurable basis for that decision. In the first year after treatment, 72 percent of patients achieved a 50 percent to 100 percent reduction in surgeries, increasing to 86 percent in the second year, according to Yahoo Finance.

Q2 loss narrows sharply

Inovio reported no revenue and a Q2 2026 net loss of USD 6.0 million, or USD 0.07 per share, compared with a USD 23.5 million loss, or USD 0.61 per share, in Q2 2025. That comparison is the clearest financial improvement in the latest report.

Total operating expenses fell to USD 18.6 million in Q2 2026, while cash, cash equivalents and short-term investments stood at USD 36.7 million on June 30, 2026. StockTitan reported that a USD 13.9 million non-cash warrant-liability gain contributed to the narrower loss.

Stock stays below yearly high

The September 23 quote was USD 1.25 on Nasdaq, against a 52-week range of USD 0.56 to USD 2.72. The share price therefore sat 54.0 percent below the 52-week high, making the October FDA date more important for valuation than the quarter's reduced loss alone.

For investors, the setup combines a clear binary regulatory date with a smaller quarterly loss and a still-low share price. The next material checkpoint is October 30, 2026.

More news and analyses on Inovio Pharmaceuticals stock